Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

Novartis drug Pelacarsen that targets Lp(a) cholesterol is in global phase 3 trials. Last year, the company launched ...

Both are antisense-based therapeutics. Eli Lilly meanwhile has an RNA interference drug lepodisiran that could be dosed once a year is in phase 3, as well as a daily oral candidate called ...

The potential advantage of that is unclear for now, as Amgen has suggested, for example, that lepodisiran could be effective even if dosed as infrequently as once per year. AZ said adding ...

If approved, the company is confident in its ability to Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...